GuiDeCode
Calcs › ⬡ Gastroenterology / Hepatology

Mayo Score / Disease Activity Index (DAI) for Ulcerative Colitis

Quantifies disease activity in ulcerative colitis using clinical and endoscopic parameters to guide treatment decisions

Calculator

Loading calculator…

Why use it

UC is a chronic relapsing-remitting inflammatory bowel disease affecting approximately 5 million people worldwide. The Mayo Score provides a standardized, validated composite assessment of clinical and endoscopic disease activity that directly guides treatment decisions — from aminosalicylate therapy in mild disease to biologic agents (anti-TNF, anti-integrin, JAK inhibitors) in moderate-to-severe disease, and surgical consultation in refractory or severe disease. The Mayo Endoscopic Score (MES) is now accepted as a primary endpoint for endoscopic remission in UC trials, with MES 0 (complete mucosal healing) being the target in modern treat-to-target strategies.

About

The Mayo Score (also called the Disease Activity Index, DAI) is the most widely used scoring system for assessing ulcerative colitis (UC) disease activity. Originally described by Schroeder and colleagues in the New England Journal of Medicine in 1987 for the evaluation of mesalazine, the Mayo Score comprises four subscores — stool frequency, rectal bleeding, endoscopic findings (Mayo Endoscopic Score, MES), and physician's global assessment (PGA) — each scored 0–3, generating a total score of 0–12. The full Mayo Score (including endoscopy) is the gold standard for clinical trial endpoints and treatment escalation decisions. A Partial Mayo Score (without endoscopy) comprising just the first three or the first two components is used in clinical practice for longitudinal monitoring without repeated endoscopy. The score is endorsed by the European Crohn's and Colitis Organisation (ECCO) and used by regulatory agencies (FDA, EMA) as the primary endpoint in UC drug trials.

When to use

  • At baseline assessment of a patient with known or suspected UC to establish disease severity
  • Before initiating or escalating biologic or immunosuppressive therapy — documents disease severity
  • At follow-up endoscopy to assess mucosal healing (treat-to-target strategy)
  • During acute hospitalization for severe/fulminant UC flare
  • Clinical trial enrollment and endpoint assessment
  • Determining need for surgical referral (total Mayo Score ≥10, or failure of medical therapy)
  • Partial Mayo Score (without endoscopy): routine monitoring at outpatient visits

Formula

Mayo Score / Disease Activity Index (DAI) — 4 subscores, each 0–3: 1. STOOL FREQUENCY: 0 = Normal (no increase) 1 = 1–2 stools/day more than normal 2 = 3–4 stools/day more than normal 3 = ≥5 stools/day more than normal 2. RECTAL BLEEDING: 0 = None 1 = Streaks of blood in ≤50% of stools 2 = Obvious blood in most stools 3 = Blood alone (no stool) 3. MAYO ENDOSCOPIC SCORE (MES): 0 = Normal or inactive (no friability, no erosions, no ulcers) 1 = Mild — erythema, decreased vascular pattern, mild friability 2 = Moderate — marked erythema, absent vascular pattern, friability, erosions 3 = Severe — spontaneous bleeding, ulceration 4. PHYSICIAN'S GLOBAL ASSESSMENT (PGA): 0 = Normal 1 = Mild disease 2 = Moderate disease 3 = Severe disease Total: 0–12 0–2: Remission 3–5: Mild UC 6–10: Moderate UC 11–12: Severe UC Partial Mayo Score (without endoscopy): Subscores 1 + 2 + 4 = 0–9 Clinical response: ≥3-point reduction AND ≥30% reduction from baseline AND rectal bleeding ≤1 Clinical remission: Partial Mayo ≤2 with rectal bleeding subscore = 0

Pearls & pitfalls

  • The Mayo Endoscopic Score (MES) is now used as a standalone primary endpoint in many UC trials — MES 0 (normal or inactive disease) represents complete mucosal healing, which is associated with the lowest relapse rates.
  • The treat-to-target strategy in UC aims for MES 0–1 (at minimum) AND clinical remission — studies show MES 0 (vs MES 1) is associated with significantly better outcomes.
  • Partial Mayo Score (stool frequency + rectal bleeding + PGA, total 0–9) is used between endoscopies for monitoring — response is ≥2-point reduction AND ≥25% reduction from baseline.
  • Severe UC (Mayo ≥10, MES 3, or meeting Truelove-Witts criteria for acute severe UC) carries mortality risk and requires urgent hospitalization.
  • The Physician's Global Assessment (PGA) subscore introduces subjectivity — it should integrate all clinical information holistically, not simply average the other subscores.
  • Fecal calprotectin is increasingly used as a non-invasive surrogate for mucosal inflammation to reduce reliance on repeated endoscopy in monitoring — a fecal calprotectin <150–250 µg/g correlates with endoscopic remission.
  • Rectal bleeding subscore is one of the most sensitive markers of disease flare — any increase from 0 (none) to ≥1 should prompt clinical reassessment.
  • Biologic therapy (anti-TNF: infliximab, adalimumab, golimumab; anti-integrin: vedolizumab; anti-IL-12/23: ustekinumab; JAK inhibitors: tofacitinib, upadacitinib) is indicated for moderate-to-severe UC (Mayo 6–12) failing aminosalicylate and/or steroid therapy.
  • Colonoscopic surveillance for colorectal cancer should begin 8–10 years after disease onset in all UC patients with disease extent beyond the rectum.

Next steps

Total Mayo Score 0–2 (Remission): Maintain current therapy. No escalation needed. Consider taper of corticosteroids if applicable. Total Mayo Score 3–5 (Mild): Optimize 5-ASA dose. Add rectal mesalazine or rectal steroids if distal disease. Total Mayo Score 6–10 (Moderate): Consider oral steroids for induction. Escalate to immunosuppressants (azathioprine, 6-MP) or biologic therapy (anti-TNF, vedolizumab, ustekinumab). Gastroenterology specialist referral. Total Mayo Score 11–12 (Severe): Hospitalization usually required. IV methylprednisolone 40–60 mg/day. If no improvement by Day 3 (Oxford criteria), consider salvage therapy (infliximab 5 mg/kg or cyclosporine 2–4 mg/kg/day) or surgical colectomy. Colorectal surgery consultation early.

Evidence

Schroeder KW et al. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med. 1987;317(26):1625-1629. PMID:3317057. Lewis JD et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14(12):1660-1666. FDA guidance documents on clinical trial endpoints for UC drugs (2016). ECCO Guidelines: Magro F et al. European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis. 2013;7(10):827-851.

References

  1. Schroeder KW et al. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med. 1987;317(26):1625-1629. — link
  2. Lewis JD et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14(12):1660-1666. — link
  3. Colombel JF et al. Ninth international symposium on inflammatory bowel disease: the STRIDE-II consensus update on Selecting Therapeutic Targets in IBD. Gut. 2018;67(7):1202-1210. — link
  4. Magro F et al. ECCO position on harmonisation of Crohn's disease endoscopic findings in registry-based studies. J Crohns Colitis. 2013;7(10):827-851. — link